Heterogeneity of response to biologic treatment: Perspective for psoriasis

Journal of Investigative Dermatology

Volumn 134, Issue 1, 2014, Pages 18-23

  Edson Heredia, Emily ^a   Sterling, Kimberly L ^a   Alatorre, Carlos I ^a   Cuyun Carter, Gebra ^a   Paczkowski, Rosirene ^a   Zarotsky, Victoria ^b   Maeda Chubachi, Tomoko ^a  

^a ELI LILLY AND COMPANY   (United States)

^b OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ALCOHOL CONSUMPTION; BIOLOGICAL THERAPY; BODY MASS; BODY WEIGHT; DISEASE DURATION; DISEASE SEVERITY; ETHNICITY; HUMAN; LIFESTYLE; ONSET AGE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR; SMOKING; TREATMENT RESPONSE;

EID: 84890969258     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.326     Document Type: Article

References (35)

1. Alatorre CI, Carter GC, Chen C et al. (2011) A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas. Int J Clin Pract 65: 831-47
2. Antoniou C, Dessinioti C, Stratigos A et al. (2009) Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience. J Eur Acad Dermatol Venereol 23: 979-82
3. Bardazzi F, Balestri R, Baldi E et al. (2010) Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther 23(Suppl 1):S14-9
4. Cantrell RA, Alatorre CI, Davis EJ et al. (2010) A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 2: 845-57
5. Carter GC, Cantrell RA, Zarotsky V et al. (2012) Comprehensive review of factors implicated in the heterogeneity of response in depression. Depress Anxiety 29: 340-54
6. Clark L, Lebwohl M (2008) The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 58: 443-446
7. Duarte AA, Chehin FB (2011) Moderate to severe psoriasis treated with infliximab - 53 patients: patients profile, efficacy and adverse effects. An Bras Dermatol 86: 257-63
8. Driessen RJ, Boezeman JB, van de Kerkhof PC et al. (2009) Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 160: 670-5
9. Fredriksson T, Pettersson U (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157: 238-44
10. Gerdes S, Mrowietz U (2009) Impact of comorbidities on the management of psoriasis. Curr Probl Dermatol 38: 21-36
11. Goetz I, Carter GC, Lucero M et al. (2011) Review of treatment response in rheumatoid arthritis: assessment of heterogeneity. Curr Med Res Opin 27: 697-711
12. Gordon K, Korman N, Frankel E et al. (2006b) Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 54(3 Suppl 2): S101-11
13. Gordon KB, Langley RG, Leonardi C et al. (2006a) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55: 598-606
14. Greenfield S, Kravitz R, Duan N et al. (2007) Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 120 (Suppl 1):S3-9
15. Iwashige K, Kouda K, Kouda M et al. (2004) Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. J Physiol Anthropol Appl Human Sci 23: 19-24
16. Kimball AB, Gladman D, Gelfand JM et al. for the National Psoriasis Foundation (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58: 1031-42
17. Kravitz RL, Duan N, Braslow J (2004) Evidencebased medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82: 661-87
18. Lebwohl M, Yeilding N, Szapary P et al. (2010) Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 63: 571-9
19. Li W, Han J, Choi HK et al. (2012) Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 175: 402-13
20. Maniscalco M, Zedda A, Faraone S et al. (2008) Weight loss and asthma control in severely obese asthmatic females. Respir Med 102: 102-8
21. Mazzotta A, Esposito M, Costanzo A et al. (2009) Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 10: 319-24
22. Menter A, Gordon KB, Leonardi CL et al. (2010b) Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 63: 448-56
23. Menter A, Gottlieb A, Feldman SR et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section I. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58: 826-50
24. Menter A, Korman NJ, Elmets CA et al. (2009b) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61: 451-85
25. Menter A, Korman NJ, Elmets CA et al. (2010a) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 62: 114-35
26. Menter A, Korman NJ, Elmets CA et al. (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 65: 137-74
27. Na JI, Kim JH, Park KC et al. (2008) Low-dose etanercept therapy in moderate to severe psoriasis in Korean. J Dermatol 35: 484-90
28. Naldi L, Addis A, Chimenti S et al. (2008) Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 217: 365-73
29. Neimann AL, Porter SB, Gelfand JM (2006) The epidemiology of psoriasis. Expert Rev Dermatol 1: 63-75
30. Papp KA, Langley RG, Lebwohl M et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-84
31. Pathirana A, Ormerod AD, Saiag P et al. (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venerol 23(Suppl 2): 1-70
32. Rakkhit T, Panko JM, Christensen TE et al. (2009) Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response. Br J Dermatol 160: 1083-9
33. Reich K, Gottlieb AB, Kimball A et al. (2006) Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials. J Am Acad Dermatol 54(Suppl): AB215
34. Strober B, Gottlieb A, Leonardi C et al. (2006) Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J Am Acad Dermatol 54: AB220
35. Zhu KJ, Zhu CY, Fan YM (2012) Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol 39: 770-3